Monograph Details
|
|
Dermatological Disorders
> Miscellaneous dermatological conditions
|
|
AVAGE |
| Manufacturer |
|
Allergan |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Retinoid. |
| Generic Name |
|
Tazarotene 0.1%; crm. |
| Indications |
|
Adjunct to comprehensive skin care and sunlight avoidance programs in the palliation of facial fine wrinkles, facial mottled hyper- and hypopigmentation, and facial benign lentigines. |
| Children |
|
<17 years: not recommended. |
| Adults |
|
≥17 years: apply thin film to entire face once daily in the PM. Women of childbearing potential: begin therapy during normal menses. |
| Contraindications |
|
Pregnancy (Cat.X). |
| Precautions |
|
Do not use to treat lentigo maligna. Obtain reliable negative pregnancy test within 2 weeks before beginning therapy; use effective contraception. Do not use on broken, eczematous, or sunburned skin. Sun sensitivity. Avoid eyes, mouth, sun, and UV light. Increased irritation in extreme weather. Discontinue or reduce dose frequency if excessive irritation occurs. Nursing mothers. |
| Interactions |
|
Avoid use until the effects of strong drying agents have subsided. Caution with irritants or photosensitizers. |
| Adverse Reactions |
|
Desquamation, erythema, burning, dry skin, pruritus, stinging, other local reactions. |
| How Supplied |
|
Crm—30g |
|
|
|
|
